
Biotech is back – and it's playing for keeps. President Donald Trump's second-term policies have unleashed a staggering ~$350 billion surge in U.S.-based pharmaceutical and biotech investments, from domestic manufacturing to cutting-edge R&D. For investors, it's a rare opportunity: major drugmakers are expanding fast, and some could be poised to deliver serious portfolio gains.
- Track biotech stocks via XBI ETF here.